ATX 3.85% 12.5¢ amplia therapeutics limited

Ann: Preliminary Final Report and Annual Report YE 31 March 2024, page-6

  1. 1,849 Posts.
    lightbulb Created with Sketch. 33
    absolutely and the first part of the trial just passed was short and mixed dose. The one being recruited for will be representative and potentially show enhanced data points with the best dose and duration. I also read somewhere might have been on one of these threads that they feel it’s one of more potent fak inhibitors in vitro so far based on comparative data but I might be wrong. Dyor
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
12.5¢
Change
-0.005(3.85%)
Mkt cap ! $34.27M
Open High Low Value Volume
13.0¢ 13.0¢ 12.0¢ $120.7K 983.7K

Buyers (Bids)

No. Vol. Price($)
2 279677 12.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.5¢ 16317 1
View Market Depth
Last trade - 15.44pm 23/08/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.